BridgeMD
New treatment option for Endometriosis (Diagnosis)
Official title Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.
ClinicalTrials.gov ID: NCT07393958
What this study is testing
- What it's testing
- This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM)...
- Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or...
- Presence of pelvic pain (VAS \> 4) during the last three months.
- No indication for surgical intervention at the time of inclusion in the study.
- Patients who are able to provide informed consent.
You likely can't join if
- Patients under 18 years of age.
- Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
- Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
- Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.
- Patients with known allergy or hypersensitivity to Doliral®.
- Pregnant or breastfeeding patients.
See the full eligibility criteria
- Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.
- Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound.
- Presence of pelvic pain (VAS \> 4) during the last three months.
- No indication for surgical intervention at the time of inclusion in the study.
- Patients who are able to provide informed consent.
- Patients under 18 years of age.
- Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
- Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
- Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.
- Patients with known allergy or hypersensitivity to Doliral®.
- Pregnant or breastfeeding patients.
- Patients on sick leave: \> 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.
The study team makes the final eligibility decision.
Where it's taking place
- Barcelona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.